Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 08 04:00PM ET
Dollar change
Percentage change
Index- P/E1.32 EPS (ttm)1.27 Insider Own3.03% Shs Outstand37.21M Perf Week-2.33%
Market Cap62.51M Forward P/E4.29 EPS next Y0.39 Insider Trans0.00% Shs Float36.08M Perf Month-9.19%
Income72.20M PEG- EPS next Q-0.11 Inst Own44.29% Short Float / Ratio4.40% / 4.70 Perf Quarter-50.73%
Sales135.87M P/S0.46 EPS this Y201.90% Inst Trans-0.19% Short Interest1.59M Perf Half Y-39.13%
Book/sh2.47 P/B0.68 EPS next Y-73.83% ROA55.36% Target Price8.12 Perf Year-8.20%
Cash/sh2.38 P/C0.71 EPS next 5Y- ROE132.23% 52W Range1.15 - 3.87 Perf YTD7.69%
Dividend- P/FCF- EPS past 5Y30.97% ROI67.81% 52W High-56.59% Beta2.03
Dividend %- Quick Ratio6.88 Sales past 5Y-42.85% Gross Margin98.60% 52W Low46.09% ATR0.11
Employees36 Current Ratio7.66 Sales Q/Q13.10% Oper. Margin53.91% RSI (14)45.08 Volatility4.78% 6.04%
OptionableYes Debt/Eq0.16 EPS Q/Q94.11% Profit Margin53.14% Rel Volume0.42 Prev Close1.70
ShortableYes LT Debt/Eq0.16 EarningsNov 13 AMC Payout- Avg Volume337.89K Price1.68
Recom1.00 SMA200.96% SMA50-9.38% SMA200-33.08% Volume140,586 Change-1.18%
Date Action Analyst Rating Change Price Target Change
Jan-22-21Initiated Guggenheim Buy $25
Jan-06-21Initiated Cantor Fitzgerald Overweight $30
Jul-11-18Upgrade Needham Hold → Buy $5
Jun-27-18Initiated Maxim Group Buy $6
Oct-24-17Initiated Guggenheim Buy $6
Jul-10-17Initiated ROTH Capital Buy $8.50
May-09-17Downgrade Needham Buy → Hold
Mar-03-17Reiterated RBC Capital Mkts Outperform $15 → $11
Oct-20-16Initiated H.C. Wainwright Buy $14
Oct-07-16Upgrade WBB Securities Buy → Strong Buy $8
Nov-27-23 10:33AM
Nov-15-23 01:15PM
Nov-13-23 05:55PM
Oct-24-23 08:00AM
09:00PM Loading…
Oct-18-23 09:00PM
Oct-16-23 08:00AM
Oct-02-23 09:00PM
Sep-27-23 08:31PM
Sep-25-23 08:55AM
Sep-20-23 04:00AM
Sep-04-23 01:31PM
Aug-28-23 10:17PM
04:59PM Loading…
Aug-14-23 04:59PM
Aug-11-23 09:09AM
Jul-20-23 09:58AM
Jun-26-23 02:20PM
Jun-21-23 07:00AM
Jun-15-23 04:10PM
May-19-23 09:22AM
May-12-23 08:00AM
May-11-23 08:45AM
May-08-23 03:38PM
Apr-13-23 08:30AM
01:33PM Loading…
Apr-11-23 01:33PM
Mar-31-23 12:31PM
Mar-30-23 01:12PM
Mar-22-23 09:25AM
Mar-01-23 04:03PM
Jan-14-23 07:43AM
Dec-01-22 08:00AM
Nov-30-22 08:30AM
Nov-17-22 08:30AM
Nov-11-22 05:37AM
Nov-09-22 08:15AM
Nov-07-22 08:30AM
Nov-03-22 08:30AM
Nov-02-22 10:01AM
Nov-01-22 08:30AM
Oct-25-22 08:30AM
Oct-24-22 08:30AM
Oct-20-22 07:00AM
Oct-11-22 08:30AM
Oct-07-22 09:25AM
Sep-09-22 08:30AM
Sep-08-22 08:30AM
Sep-01-22 08:30AM
Aug-15-22 08:15AM
Aug-09-22 08:30AM
Aug-04-22 08:30AM
Aug-01-22 08:30AM
Jul-19-22 08:30AM
Jul-14-22 08:30AM
Jun-29-22 07:06AM
Jun-23-22 08:30AM
Jun-08-22 08:30AM
Jun-03-22 04:05PM
May-20-22 08:30AM
May-12-22 08:35AM
May-10-22 08:30AM
May-05-22 08:30AM
May-04-22 08:30AM
Apr-30-22 08:55AM
Apr-27-22 08:30AM
Apr-26-22 05:18PM
Apr-22-22 08:15AM
Apr-21-22 04:01PM
Apr-20-22 08:30AM
Apr-19-22 08:30AM
Apr-09-22 08:03AM
Apr-04-22 09:59AM
Mar-31-22 01:37PM
Mar-29-22 08:15AM
Mar-24-22 08:30AM
Mar-08-22 08:30AM
Mar-04-22 05:00PM
Mar-02-22 08:30AM
Feb-13-22 07:43AM
Feb-10-22 07:36AM
Feb-03-22 04:15PM
Jan-20-22 10:13AM
Jan-06-22 01:03PM
Dec-22-21 08:30AM
Dec-20-21 08:30AM
Dec-15-21 08:30AM
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.